News
The FDA's Oncologic Drugs Advisory Committee has casted their votes on the utilization of certain treatments in the multiple ...
In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...
The anemia treatment missed its main goal in a myelofibrosis study. Meanwhile, Blenrep's return to the U.S. market may have ...
2d
GlobalData on MSNGSK’s Blenrep US comeback hindered by eye safety concernsFDA reviewers have identified high rates of ocular toxicity as GSK looks to place its blood cancer drug back on the market.
UK pharma major GSK is seeking US approval for Blenrep (belantamab mafodotin) in two multiple myeloma indications.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results